Radius Health (RDUS) Gives Presentation on Abaloparatide Transdermal Patch Development Program at ASBMR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks rattled, Treasuries rally after Israel attacks Iran
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Oil surges as reports of Israeli strike on Iran roil markets
- Reports of Israeli attack on Iran spark rush to Swiss franc and yen
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Radius Presents Abaloparatide Transdermal Patch Development Program at American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting
September 19, 2016 1:00 PM EDT-Second Generation Transdermal Patch Achieves Pharmacokinetic Objectives
WALTHAM, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Radius Health Inc. (Nasdaq: RDUS) a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases today gave an oral presentation at the Late-Breaking Abstract Session titled Clinical Development of an Optimized Abaloparatide Transdermal Patch at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting, at the Georgia World Congress Center in Atlanta, Georgia.
This is the first successful application of formulation technology to enable alterations in the... More
Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR
September 18, 2016 7:30 AM EDTWALTHAM, Mass., Sept. 18, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that additional positive results from the Phase 3 ACTIVE (Abaloparatide Comparator Trial... More
